Difference between revisions of "Part:BBa K1621004:Design"

(→‎References)
m (→‎References)
Line 23: Line 23:
 
<br>
 
<br>
 
<br>
 
<br>
−
Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA (2009). Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. ''Protein Pept Lett'' 16(7):842–850.
+
Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA (2009). Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from ''in silico'' design to ''in vitro'' and primary ''in vivo'' analyses in BALB/c mice. ''Protein Pept Lett'' 16(7):842–850.
 
<br>
 
<br>

Revision as of 09:30, 30 August 2015


gag/tat/pol/env - polyepitopic antigen derived from HIV-1


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The sequence was codon optimized for expression in E.coli with the codon optimization tool from IDT.


Source

The sequence for this part was obtained from Jafarpour et al. (2014) and synthesized by Integrated DNA Technologies.

References


Goepfert PA (2003). Making sense of the HIV immune response. Top HIV Med 11(1):4–8.

Jafarpour N, Memarnejadian A, Aghasadeghi MR, Kohram F, Aghababa H, Khoramabadi N, Mahdavi M (2014). Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. Mol Biol Rep 41:5207–5214.

Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA (2009). Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 16(7):842–850.